| Betterchem |

|
|
| FDA approval activities
for this prescription drug:
Novantrone (mitoxantrone for Injection Concentrate), Serono, NDA 19-297/S25, S26 & S27 1/13/03 1/23/03 Novantrone (mitoxantrone for Injection Concentrate), Immunex NDA 19-297/S-024 2/20/02 2/21/02 Novantrone (mitoxantrone for Injection Concentrate), Immunex NDA 19-297/S-021 2/04/00 6/4/01 Novantrone (mitoxantrone hydrochloride) Injection,Rx Immunex NDA 21-120 10/13/00 Novantrone Indications: reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis. |
|
© 2009 Betterchem.com
|